Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383901445> ?p ?o ?g. }
- W4383901445 endingPage "101568" @default.
- W4383901445 startingPage "101568" @default.
- W4383901445 abstract "•We investigated the impact of sex on first-line treatment in RAS wild-type metastatic colorectal cancer.•Female patients had a higher rate of any grade nausea, diarrhea and stomatitis.•Male patients benefitted significantly from the addition of panitumumab in regard to PFS during maintenance.•Future trials should use sex as a standard stratification factor. BackgroundClinical trials in metastatic colorectal cancer (mCRC) are usually conducted irrespective of sex. Sex-associated differences relating to safety and efficacy in the treatment of mCRC, however, are gaining interest.MethodsPanaMa investigated the efficacy of panitumumab (Pmab) plus fluorouracil and folinic acid (FU/FA) versus FU/FA alone after induction therapy with six cycles of FU/FA and oxaliplatin plus Pmab in patients with RAS wild-type mCRC. In this post hoc analysis, the study population was stratified for sex. Evaluated efficacy endpoints during maintenance treatment were progression-free survival (PFS, primary endpoint of the trial), overall survival (OS) and objective response rate during maintenance therapy. Safety endpoints were rates of any grade and grade 3/4 adverse events during maintenance therapy.ResultsIn total, 165 male and 83 female patients were randomized and treated. Male and female patients showed numerically better objective response rates with Pmab, without reaching statistical significance. Male patients derived a significant benefit from the addition of Pmab to maintenance treatment with regard to PFS [hazard ratio (HR) 0.63; 95% confidence interval (CI) 0.45-0.88; P = 0.006] that was not observed in female patients (HR 0.85; 95% CI 0.53-1.35; P = 0.491). The better PFS for male patients treated with Pmab did not translate into improved OS (HR 0.85; 95% CI 0.55-1.30; P = 0.452). Female patients showed numerically improved OS when treated with Pmab. There was no difference in the total of grade ≥3 adverse events during maintenance regarding sex (P = 0.791). Female patients, however, had a higher rate of any grade nausea, diarrhea and stomatitis.ConclusionsIn the PanaMa trial, the addition of Pmab to maintenance treatment of RAS wild-type mCRC with FU/FA improved the outcome in terms of the primary endpoint (PFS) particularly in male patients. Female patients did not show the same benefit while experiencing higher rates of adverse events. Our results support the development of sex-specific protocols. Clinical trials in metastatic colorectal cancer (mCRC) are usually conducted irrespective of sex. Sex-associated differences relating to safety and efficacy in the treatment of mCRC, however, are gaining interest. PanaMa investigated the efficacy of panitumumab (Pmab) plus fluorouracil and folinic acid (FU/FA) versus FU/FA alone after induction therapy with six cycles of FU/FA and oxaliplatin plus Pmab in patients with RAS wild-type mCRC. In this post hoc analysis, the study population was stratified for sex. Evaluated efficacy endpoints during maintenance treatment were progression-free survival (PFS, primary endpoint of the trial), overall survival (OS) and objective response rate during maintenance therapy. Safety endpoints were rates of any grade and grade 3/4 adverse events during maintenance therapy. In total, 165 male and 83 female patients were randomized and treated. Male and female patients showed numerically better objective response rates with Pmab, without reaching statistical significance. Male patients derived a significant benefit from the addition of Pmab to maintenance treatment with regard to PFS [hazard ratio (HR) 0.63; 95% confidence interval (CI) 0.45-0.88; P = 0.006] that was not observed in female patients (HR 0.85; 95% CI 0.53-1.35; P = 0.491). The better PFS for male patients treated with Pmab did not translate into improved OS (HR 0.85; 95% CI 0.55-1.30; P = 0.452). Female patients showed numerically improved OS when treated with Pmab. There was no difference in the total of grade ≥3 adverse events during maintenance regarding sex (P = 0.791). Female patients, however, had a higher rate of any grade nausea, diarrhea and stomatitis. In the PanaMa trial, the addition of Pmab to maintenance treatment of RAS wild-type mCRC with FU/FA improved the outcome in terms of the primary endpoint (PFS) particularly in male patients. Female patients did not show the same benefit while experiencing higher rates of adverse events. Our results support the development of sex-specific protocols." @default.
- W4383901445 created "2023-07-12" @default.
- W4383901445 creator A5012380788 @default.
- W4383901445 creator A5013028677 @default.
- W4383901445 creator A5028841026 @default.
- W4383901445 creator A5031812055 @default.
- W4383901445 creator A5037011093 @default.
- W4383901445 creator A5037754184 @default.
- W4383901445 creator A5039743409 @default.
- W4383901445 creator A5043755888 @default.
- W4383901445 creator A5049026435 @default.
- W4383901445 creator A5049518897 @default.
- W4383901445 creator A5055766851 @default.
- W4383901445 creator A5061986111 @default.
- W4383901445 creator A5063940692 @default.
- W4383901445 creator A5067138413 @default.
- W4383901445 creator A5068912139 @default.
- W4383901445 creator A5069246337 @default.
- W4383901445 creator A5069585976 @default.
- W4383901445 creator A5077797736 @default.
- W4383901445 creator A5088129649 @default.
- W4383901445 creator A5091422927 @default.
- W4383901445 date "2023-08-01" @default.
- W4383901445 modified "2023-10-02" @default.
- W4383901445 title "Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)" @default.
- W4383901445 cites W1845493768 @default.
- W4383901445 cites W1990692976 @default.
- W4383901445 cites W2005348280 @default.
- W4383901445 cites W2006569509 @default.
- W4383901445 cites W2057975842 @default.
- W4383901445 cites W2091289833 @default.
- W4383901445 cites W2093820571 @default.
- W4383901445 cites W2095201384 @default.
- W4383901445 cites W2098354753 @default.
- W4383901445 cites W2109498035 @default.
- W4383901445 cites W2112570485 @default.
- W4383901445 cites W2129998117 @default.
- W4383901445 cites W2147513363 @default.
- W4383901445 cites W2159179344 @default.
- W4383901445 cites W2168579528 @default.
- W4383901445 cites W2266030680 @default.
- W4383901445 cites W2338977782 @default.
- W4383901445 cites W2419577768 @default.
- W4383901445 cites W2470575266 @default.
- W4383901445 cites W2605964154 @default.
- W4383901445 cites W2712978371 @default.
- W4383901445 cites W2795004907 @default.
- W4383901445 cites W2804772768 @default.
- W4383901445 cites W2804842157 @default.
- W4383901445 cites W2808002745 @default.
- W4383901445 cites W2891670496 @default.
- W4383901445 cites W2899140013 @default.
- W4383901445 cites W2910076548 @default.
- W4383901445 cites W2946644285 @default.
- W4383901445 cites W2954058010 @default.
- W4383901445 cites W2954681275 @default.
- W4383901445 cites W2980659545 @default.
- W4383901445 cites W2980963825 @default.
- W4383901445 cites W3031005736 @default.
- W4383901445 cites W3081342720 @default.
- W4383901445 cites W3128646645 @default.
- W4383901445 cites W3134581972 @default.
- W4383901445 cites W3134835510 @default.
- W4383901445 cites W3166005657 @default.
- W4383901445 cites W3193447626 @default.
- W4383901445 cites W3198895466 @default.
- W4383901445 cites W4211168195 @default.
- W4383901445 cites W4226248999 @default.
- W4383901445 cites W4229008038 @default.
- W4383901445 cites W4250481919 @default.
- W4383901445 cites W4285742743 @default.
- W4383901445 cites W4286437555 @default.
- W4383901445 cites W580033162 @default.
- W4383901445 doi "https://doi.org/10.1016/j.esmoop.2023.101568" @default.
- W4383901445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37441876" @default.
- W4383901445 hasPublicationYear "2023" @default.
- W4383901445 type Work @default.
- W4383901445 citedByCount "0" @default.
- W4383901445 crossrefType "journal-article" @default.
- W4383901445 hasAuthorship W4383901445A5012380788 @default.
- W4383901445 hasAuthorship W4383901445A5013028677 @default.
- W4383901445 hasAuthorship W4383901445A5028841026 @default.
- W4383901445 hasAuthorship W4383901445A5031812055 @default.
- W4383901445 hasAuthorship W4383901445A5037011093 @default.
- W4383901445 hasAuthorship W4383901445A5037754184 @default.
- W4383901445 hasAuthorship W4383901445A5039743409 @default.
- W4383901445 hasAuthorship W4383901445A5043755888 @default.
- W4383901445 hasAuthorship W4383901445A5049026435 @default.
- W4383901445 hasAuthorship W4383901445A5049518897 @default.
- W4383901445 hasAuthorship W4383901445A5055766851 @default.
- W4383901445 hasAuthorship W4383901445A5061986111 @default.
- W4383901445 hasAuthorship W4383901445A5063940692 @default.
- W4383901445 hasAuthorship W4383901445A5067138413 @default.
- W4383901445 hasAuthorship W4383901445A5068912139 @default.
- W4383901445 hasAuthorship W4383901445A5069246337 @default.
- W4383901445 hasAuthorship W4383901445A5069585976 @default.
- W4383901445 hasAuthorship W4383901445A5077797736 @default.
- W4383901445 hasAuthorship W4383901445A5088129649 @default.